A deep brain stimulation lead includes a distal end portion having a length of greater than 5 millimeters and a largest outer diametric dimension of 1 millimeter or less. One or more electrodes are disposed at the distal end portion. The lead also includes a proximal end portion having one or more contacts electrically coupled to the one or more electrodes. The lead further includes a mid portion between the proximal end portion and the distal end portion. The mid portion has an outer diametric dimension of greater than 1 millimeter and is configured and positioned to be located in proximity to a burr hole of a skull of patient when the distal end portion is positioned in the brain of the patient at a location to deliver a signal to a target region. #1#
|
#1# 1. An implantable brain stimulation lead comprising:
a distal end portion having a length of 20 millimeters or greater and a largest outer diametric dimension of 1 millimeter or less;
one or more electrodes disposed at the distal end portion;
a proximal end portion having one or more contacts electrically coupled to the one or more electrodes; and
a mid portion between the proximal end portion and the distal end portion, the mid portion having an outer diametric dimension of greater than 1 millimeter and configured and positioned to be located at a burr hole of a skull of a patient when the distal end portion is positioned in the brain of the patient,
wherein the distal end portion is the only portion extending distally from the mid portion.
#1# 14. A method comprising:
inserting a distal end portion of a lead into parenchymal tissue of a brain, wherein the distal end portion of the lead that is inserted into a brain has an outer diameter of 1 millimeter or less and a length of 2 millimeters or more;
anchoring a mid portion of the lead at a burr hole in a skull, the mid portion of the lead having an outer diameter of greater than 1 millimeter,
wherein the mid portion is immediately proximal to the distal end portion, and
wherein the distal end portion of the lead has a length of 20 millimeters or more and accounts for 90% or more of the lead that is inserted into the parenchymal tissue when the lead is properly positioned in the brain, and wherein the distal end portion is the only portion extending distally from the mid portion.
#1# 2. The lead of
#1# 3. The lead of
#1# 4. The lead of
#1# 5. The lead of
#1# 6. The lead of
#1# 7. The lead of
#1# 8. The lead of
#1# 9. The lead of
#1# 10. A method for manufacturing a lead according to
extending, in a linear manner each of the more than one conductors from a proximal portion of the distal end portion to one of the electrodes;
electrically coupling each of the more than one electrodes to one of the electrodes; and
embedding the more than one conductors in polymeric material such that no luminal void exists between the more than one conductors.
#1# 11. The method of
#1# 12. The method of
#1# 13. A method for manufacturing a lead according to
extending, in a linear manner, each of the more than one individually insulated conductors from a proximal portion of the distal end portion to one of the electrodes;
braiding the more than one linearly extended individually insulated conductors around each other;
electrically coupling each of the more than one electrodes to one of electrodes; and
embedding the more than one individually insulated conductors in polymeric material such that no luminal void exists between the more than one individually insulated conductors.
#1# 15. The method of
#1# 16. The method of
#1# 17. The method of
#1# 18. The method of
|
This application relates to medical devices; and more particularly to implantable medical leads for applying electrical signals to deep brain structures.
Implantable neurostimulators have been used or suggested to treat a variety of neurological diseases. In some cases, electrical signals generated by the neurostimulators are applied to regions or structures of the brain via electrodes of leads operably coupled to the stimulator. Often the brain regions or structures that are targeted are very small. As a result, it can be difficult to properly place a lead such that the signal may be applied to the desired target. In addition, placement of leads having large outer diameters into the brain can cause undesired injury to tissue, which in some cases may be the tissue for which therapy is directed.
The present disclosure describes, among other things, leads that have thin distal ends. Because of the thin distal ends, the leads can be implanted in a patient's brain without causing as much damage as thicker leads. In some cases multiple leads having thin distal ends can be placed in a patient's brain so that the combination of leads can better capture the desired brain region or structure. When multiple leads are placed in a patient's brain, reduced tissue damage associated with thinner leads is further appreciated.
In various embodiments described herein, an implantable deep brain stimulation lead includes a distal end portion having a length of greater than 2 millimeters and a largest outer diametric dimension of 1 millimeter or less. One or more electrodes are disposed at the distal end portion. The lead also includes a proximal end portion having one or more contacts electrically coupled to the one or more electrodes. The lead further includes a mid portion between the proximal end portion and the distal end portion. The mid portion has an outer diametric dimension of greater than 1 millimeter and is configured and positioned to be located in proximity to a burr hole of a skull of patient when the distal end portion is positioned in the brain of the patient at a location to deliver a signal to a target region.
In numerous embodiments described herein, a method for manufacturing a lead includes extending, in a linear manner each of one or more conductors from a proximal portion of a distal end portion of a lead (e.g., the intersection of the distal end portion and the mid portion) to one of one or more electrodes at the distal end portion of the lead. The method further includes (i) electrically coupling each of the one or more conductors to one of the one or more electrodes; and (ii) embedding the one or more conductors in polymeric material such that no luminal void exists between the conductors.
In various embodiments described herein, a method for deep brain stimulation includes inserting a distal end portion of a lead into parenchymal tissue of a brain, wherein the distal end portion of the lead that is inserted into a brain has an outer diameter of 1 millimeter or less and a length of 10 millimeters or more. The method further includes anchoring a mid portion of the lead in proximity to a burr hole in a skull. The mid portion of the lead has an outer diameter of greater than 1 millimeter. The mid portion is immediately proximal to the distal end portion. The distal end portion of the lead accounts for 90% or more of the lead that is inserted into the parenchymal tissue when the lead is properly positioned in the brain.
By using leads having thinner distal ends as described herein, less damage may result from implantation of such leads relative to conventional deep brain stimulation leads. Due in part to the reduction in damage, more leads may be implanted to ensure that the target brain region is appropriately captured. In addition, the leads described herein may include a thicker more proximal mid sections that provide for sufficient robustness and structural integrity; e.g., to allow for proper anchoring of the lead with a burr hole cap anchor or for mechanical forces that may be imposed by bending or stretch. These and other advantages will be readily understood from the following detailed descriptions when read in conjunction with the accompanying drawings.
The drawings are not necessarily to scale. Like numbers used in the figures refer to like components, steps and the like. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the component in another figure labeled with the same number. In addition, the use of different numbers to refer to components is not intended to indicate that the different numbered components cannot be the same or similar.
In the following detailed description, reference is made to the accompanying drawings that form a part hereof, and in which are shown by way of illustration several specific embodiments of devices, systems and methods. It is to be understood that other embodiments are contemplated and may be made without departing from the scope of spirit of the present invention. The following detailed description, therefore, is not to be taken in a limiting sense.
All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” encompass embodiments having plural referents, unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
As used herein, “proximal” and “distal” refer to position relative to an implantable electrical medical device. For example, a proximal portion of a lead is a portion nearer an implantable electrical medical device, and a distal portion is a portion further from the implantable electrical medical device.
The present disclosure relates to, among other things, leads that have thin distal ends. Because of the thin distal ends, the leads can be readily implanted in a patient's brain. In some cases, multiple leads having distal ends can be placed in a patient's brain so that the combination of leads can better capture the desired brain region or structure. When multiple leads are placed in a patient's brain, advantages associated with reduced volume of thinner leads is further appreciated. While advantages of the leads may be well appreciated when used for deep brain stimulation, the leads described herein may be used for any suitable purpose with any suitable system.
An overview of an exemplary system is depicted in
Still referring to
As indicated above, the leads described herein (see, e.g.,
The portion of the lead 20 that is engaged and secured by an anchor, such as the depicted burr hole cap anchor 200, should be sufficiently robust, having sufficient structural integrity to withstand strain placed on the lead at the point or area of capture. The lead 20 proximal to the portion secured in the anchor 20 is typically subjected to a good deal of strain due to, for example, movement of the patient's head and neck or scratching of the scalp during the wound healing process which typically causes itching. To the extent that the lead 20 is held securely in the anchor 200, the portion of the lead distal to the burr hole cap anchor 200 is not subject to much strain, as the distal portion 28 of the lead is fixed relative to the patient's brain (B).
Referring now to
In various embodiments, the distal end portion 28 has a largest outer diametric dimension (d2) of less than 1 millimeter, such as between about 0.1 mm and 1 mm, between about 0.5 mm and 1 mm, or about 0.7 mm. In many embodiments the outer diametric dimension of the distal portion is uniform. As used herein “uniform” with regard to an outer diametric dimension means that the dimension does not change by more than 10% along at least 90% of the length of the distal portion 28.
In various embodiments, the mid portion 26 of the lead has an outer diametric dimension of greater than 1 millimeter, such as about 1.25 mm. This mid portion may be constructed in a manner the same as, or similar to, currently available deep brain stimulation leads, such as Medtronic, Inc.'s Model 3387 or 3389 DBS lead, or as otherwise generally known in the art.
Preferably, the lead is designed such that the distal portion 28 extends into the brain of a patient to a desired distance while the mid portion 26 does not enter the brain parenchyma but is positioned to be captured by a burr hole anchor. Of course, as brain anatomy varies from person to person, it is not always possible for a lead to be designed and manufactured so that the thin distal portion 28 is inserted in the brain, while the mid portion 26 does not enter the parenchyma, but is positioned to be captured by the anchor. Accordingly, in some embodiments, the lead is configured such that at least 90% of the lead that is in the brain parenchymal tissue is the distal portion 28 (i.e., 10% can be mid portion 26).
The distal portion 28 can be any suitable length so that it can be placed such that electrodes are in proximity to a brain target. This length can readily be measured in using conventional sterotactic planning software, such as Medtronic, Inc.'s FrameLink™ solution. Leads with different lengths of the distal portion may be available in the operating room and the appropriate lead length may be chosen depending on the stereotactic planning of brain target and trajectory through the brain. In many embodiments, the distal portion 28 of the lead has a length of 2 mm or greater, such as 5 mm or greater, 10 mm or greater, 20 mm or greater, 30 mm or greater, 40 mm or greater, 50 mm or greater, 60 mm or greater, 70 mm or greater, 80 mm or greater, 90 mm or greater, or 100 mm or greater.
Referring now to
In the embodiment depicted in
Of course, it will be understood that
Referring now to
As shown in
Distal portions 28 of the lead may be made in any suitable manner. For example and referring to
In some embodiments, the conductors are embedded in polymeric material via molding. In some embodiments, the conductors are embedded in polymeric material by placing the conductors in a lumen of a polymeric tube (preferably the inner diameter of the lumen is only slightly larger than the outer diameter of the extended conductors—whether bundled or not), which tube is placed inside of a shrink-wrap sheath, such as a polytetrafluoroethylene or fluorinated ethylene-propylene sheath or tube. The conductor/tube/sheath assembly is heated to reflow the polymer of the tube around the conductors, while the sheath applies a restrictive force to minimize the diameter of the distal end portion of the lead. In some embodiments, the polymer in which the conductors are embedded is polyurethane. In some embodiments, epoxy is used, which may impart a stiffer structure than polyurethane. Of course, any suitable polymer may be used.
In some embodiments, stiffening elements may be included in the distal portion of the lead. For example, rods or fibers of high molecular weight or ultrahigh molecular weight polyethylene, such as Dyneema, may be included in the distal portion of the lead. In some embodiments, the polymeric material in which the conductors are embedded includes a high molecular weight or ultrahigh molecular weight polyethylene, such as Dyneema.
As discussed above, leads having thin distal end portions and thicker mid portions may be used for any purpose. However, their advantages may be readily realized when the lead is used for deep brain stimulation. An overview of a method associated with deep brain stimulation is depicted in
If the distal portion of the lead is sufficiently stiff, the distal portion may be introduced into the brain directly without use of a guide cannula. In such embodiments, it may be desirable for at least a portion to include a radiopaque or other suitable marker to allow visualization as the distal end is advanced through brain tissue. If use of a guide cannula is desired for stereotactic placement of the lead, the guide cannula preferably has an inner diameter only slightly larger than the outer diameter of the distal portion of the lead to avoid unnecessary damage to brain tissue. In many cases, such a guide cannula will not be able to be readily withdrawn over the thicker mid portion of the lead. To overcome this potential problem, the guide cannula may be in the form of a peelable sheath or the like, which would allow introduction of the distal portion of the lead into the cannula or sheath and would allow removal of the guide cannula or sheath after desired placement of the distal portion of the lead. Of course, any other suitable guide cannula or system may be employed to ensure that the lead is properly positioned.
Thus, embodiments of the LEAD HAVING THIN DISTAL END PORTION are disclosed. One skilled in the art will appreciate that the present invention can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the present invention is limited only by the claims that follow.
Van Venrooij, Paulus, Appenrodt, Peter, Gielen, Frans L H
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
5782760, | May 23 1995 | SICHUAN JINJIANG ELECTRONIC SCIENCE AND TECHNOLOGY CO , LTD | Over-the-wire EP catheter |
5843148, | Sep 27 1996 | Medtronic, Inc | High resolution brain stimulation lead and method of use |
6597953, | Feb 20 2001 | NeuroPace, Inc.; NEUROPACE, INC A DELAWARE CORPORATION | Furcated sensing and stimulation lead |
6721604, | Jul 27 2000 | ADVANCED NEUROMODULATION SYSTEMS, INC | Reduced diameter, low resistance medical electrical lead |
6952616, | Sep 26 2000 | ADVANCED NEUROMODULATION SYSTEMS, INC | Medical lead and method for electrode attachment |
7047082, | Sep 16 1999 | ADVANCED NEUROMODULATION SYSTEMS, INC | Neurostimulating lead |
7051419, | Sep 16 1999 | ADVANCED NEUROMODULATION SYSTEMS, INC | Neurostimulating lead |
20020116042, | |||
20040064174, | |||
20040111141, | |||
20050228249, | |||
20060129203, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jan 11 2011 | GIELEN, FRANS L H | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025796 | /0530 | |
Jan 11 2011 | VAN VENROOIJ, PAULUS | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025796 | /0530 | |
Jan 21 2011 | APPENRODT, PETER | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025796 | /0530 | |
Feb 11 2011 | Medtronic, Inc. | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Feb 26 2018 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Jan 20 2022 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Date | Maintenance Schedule |
Aug 26 2017 | 4 years fee payment window open |
Feb 26 2018 | 6 months grace period start (w surcharge) |
Aug 26 2018 | patent expiry (for year 4) |
Aug 26 2020 | 2 years to revive unintentionally abandoned end. (for year 4) |
Aug 26 2021 | 8 years fee payment window open |
Feb 26 2022 | 6 months grace period start (w surcharge) |
Aug 26 2022 | patent expiry (for year 8) |
Aug 26 2024 | 2 years to revive unintentionally abandoned end. (for year 8) |
Aug 26 2025 | 12 years fee payment window open |
Feb 26 2026 | 6 months grace period start (w surcharge) |
Aug 26 2026 | patent expiry (for year 12) |
Aug 26 2028 | 2 years to revive unintentionally abandoned end. (for year 12) |